Search results
Added:
1 week ago
Source:
Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,…
View more
Added:
1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott…
View more
Added:
4 months ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional…
View more
Added:
9 months ago
EuroPCR25 - Novel DynamX Bioadaptor demonstrates a sustained reduction of device-related events from six-month to three-year follow-up compared to drug-eluting stents (DES).We are joined by Dr Shigeru Saito (Shonan Kamakura General Hospital, Kamakura, JP) to discuss key findings from the BIOADAPTOR RCT trial (NCT04192747). This prospective, randomised controlled trial compared the ELX1805J …
View more
Added:
1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary…
View more
Added:
2 years ago
ESC 2023 — We are joined onsite by Dr Duk-Woo Park and Dr Do-Yoon Kang (Asan Medical Center, Seoul, KR) to discuss the findings from the OCTIVUS study (NCT03394079).
The OCTIVUS study (Seung-Jung Park, CardioVascular Research Foundation, Korea) aims to compare the clinical safety and efficacy of optimal coherence tomography (OCT) guided and intravascular ultrasound (IVUS) guided strategies in…
View more
A Pieter Kappetein
Job title: Consultant Cardiothoracic Surgeon, Professor and Chair of the residency program
Author
Added:
11 months ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
Added:
11 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Added:
4 months ago
NVM Cardiology Conference Reflections: What’s Hot at TCT 2025?Join Prof Nicolas Van Mieghem, Transcatheter Interventions Online Course Director, as he shares his critical perspective on some of the key late-breaking data highlights from TCT 2025.What should we expect from the new data? Where should we take a closer look at the existing evidence and the premise of these trials? And which results…
View more